Sienna Biopharmaceuticals (SNNA) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Sienna Biopharmaceuticals (NASDAQ:SNNA) posted its quarterly earnings results on Thursday. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.03), MarketWatch Earnings reports.

Shares of NASDAQ SNNA traded down $0.52 during midday trading on Friday, hitting $10.05. The company’s stock had a trading volume of 26,504 shares, compared to its average volume of 82,323. Sienna Biopharmaceuticals has a one year low of $8.77 and a one year high of $25.71. The company has a quick ratio of 5.82, a current ratio of 5.82 and a debt-to-equity ratio of 0.54. The firm has a market cap of $211.53 million, a P/E ratio of -1.94 and a beta of 1.48.

Several research firms have recently issued reports on SNNA. Zacks Investment Research lowered shares of Sienna Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 3rd. BMO Capital Markets lowered their price target on shares of Sienna Biopharmaceuticals from $30.00 to $27.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 1st.

An institutional investor recently raised its position in Sienna Biopharmaceuticals stock. Bank of New York Mellon Corp grew its holdings in Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) by 15.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,945 shares of the company’s stock after purchasing an additional 4,956 shares during the period. Bank of New York Mellon Corp owned approximately 0.18% of Sienna Biopharmaceuticals worth $561,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 47.46% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at

Sienna Biopharmaceuticals Company Profile

Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.

Further Reading: Technical Analysis

Earnings History for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply